Maven Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-13,177
Closed -$134K 1193
2023
Q3
$134K Buy
+13,177
New +$123K ﹤0.01% 1049
2017
Q2
Sell
-446
Closed -$14K 53
2017
Q1
$14K Sell
446
-330
-43% -$11.3K 0.01% 47
2016
Q4
$28K Buy
+776
New +$31K 0.03% 39

Other funds holding TEVA

Maven Securities's TEVA Position: Q4 2023 in Review

Maven Securities sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 13,177 shares — an estimated $134K sold.

Maven Securities first reported a position in TEVA in Q4 2016 and held it in 3 quarters. The position peaked at $134K in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Maven Securities reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 13,177 Teva Pharmaceuticals shares in Q4 2023, an estimated $134K.
  • Maven Securities first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Maven Securities's Teva Pharmaceuticals position peaked at $134K in Q3 2023.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.